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Clinics 
Age and sex 
85 years old female patient. 
Previous history 
No preleukemia. No previous malignancy. No inborn 
condition of note. 
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged lymph 
nodes, no central nervous system involvement. 
Blood 






Positive for CD10, CD19, HLA-DR, CD34 and 
cytoplasmatic TdT; CD20 is expressed on 1% of the 
cells; additionally, there is abnormal coexpression of 
CD33 and CD13. 










Date of diagnosis: 02-2010 
Treatment: Vincristine and Dexamethasone 
Complete remission : no 
Treatment related death : no 
Relapse : no  
Status: Death.  
Survival: 8 months 
Karyotype 
Sample: Bone marrow 




Other molecular cytogenetics technics 
FISH with WCP probes for chromosomes 8 and 9; 
FISH with BAC clones RP11-513D5 and RP11-
359P11. 
Other molecular cytogenetics results 
FGFR1-CEP110-fusion detected using RT-PCR. 
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Comments 
Here, we report a rare case of a t(8;9)(p12;q33) in a 
patient with c-ALL. The peripheral blood was 
infiltrated with CD10+, CD19+, CD34+, HLA-DR+ as 
well as cytoplasmatic TdT+, CD79a+ and CD22+ 
lymphoblasts. Additionally, cells showed abnormal 
coexpression of CD33 and CD13. Chromosome 
banding analysis revealed a 46,XY,t(8;9)(p12;q33) 
karyotype, and a FGFR1-CEP110 fusion transcript was 
detected by reverse transcription-polymerase chain 
reaction (RT-PCR). Patients with a t(8;9)(p12;q33) that 
have been published so far showed either a myeloid or 
biphenotypic malignancy, often presenting a 
myeloproliferative neoplasia or a myeloproliferative 
neoplasia in transformation (Chaffanet et al., 1998; 
Guasch et al., 2000; Sohal et al., 2001; Yamamoto et 
al., 2006; Mozziconacci et al., 2008; Park et al., 2008). 
Contrary to previous reports we did not observe 
myeloid involvement in our patient. Both the EGIL 
criteria for biphenotypic acute leukemia as well as the 
WHO classification for mixed phenotype acute 
leukaemia are not met here (Bene et al., 1995; 
Swerdlow et al., 2008). Thus, this is -to our knowledge- 
the first description of a patient with a t(8;9)(p12;q33), 
who presented solely with a lymphoid malignancy. 
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